Panelists discuss how Brandi first noticed symptoms leading to her paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, highlighting the challenges of the initial diagnostic process, and explore the ...

Researchers have discovered that with the dual inhibition of C5 and factor D, patients with paroxysmal nocturnal ...

The first-in-human trial is taking place at Na Homolce hospital in Prague, Czech Republic, and will treat up to 50 patients.

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today ...

Etripamil is a small molecule commercialized by Milestone Pharmaceuticals, with a leading Pre-Registration program in Supraventricular Tachycardia.

It is administered through oral route. The drug candidate acts by targeting complement factor D. It was also under development for paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia ...

These treat conditions like hypertrophic cardiomyopathy, and intractable epilepsy. China’s National Healthcare Security ...

Dr. Greenberg joins the company as it advances clinical development of its lead product, an orally inhaled treatment for ...

NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...

"Vertigo itself is a symptom of BPPV in which a person feels as if they or the objects around them are moving when they actually are stationary." ...

Regeneron will have a tough job taking on AstraZeneca’s big-selling Ultomiris in the market for paroxysmal nocturnal ...